Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 202 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Follow-Up Questions
Who is the CEO of Omeros Corp?
Dr. Gregory Demopulos is the Chairman of the Board of Omeros Corp, joining the firm since 1994.
What is the price performance of OMER stock?
The current price of OMER is $8.12, it has increased 0.18% in the last trading day.
What are the primary business themes or industries for Omeros Corp?
Omeros Corp belongs to Pharmaceuticals industry and the sector is Health Care
What is Omeros Corp market cap?
Omeros Corp's current market cap is $552.6M
Is Omeros Corp a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Omeros Corp, including 3 strong buy, 5 buy, 3 hold, 0 sell, and 3 strong sell
